Search results
Showing 496 to 510 of 600 results for diabetes
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
View quality statements for QS184Show all sections
Sections for QS184
- Quality statements
- Quality statement 1: Raising awareness – health promotion interventions
- Quality statement 2: Diagnosis
- Quality statement 3: Advance care planning
- Quality statement 4: Coordinating care
- Quality statement 5: Activities to promote wellbeing
- Quality statement 6: Managing distress
- Quality statement 7: Supporting carers
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)
This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.
In development [GID-MT538] Expected publication date: TBC
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.
NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
This guidance has been replaced by NICE guideline NG17.